New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmapheresis (Advances in Experimental Medicine and Biology, 260)

Front Matter....Pages i-viii Protein Catabolic Factors in Patients on Renal Replacement Therapy....Pages 1-9 β 2 Microglobulin-Derived Amyloid in Dialysis Patients....Pages 11-18 Mechanisms and Consequences of Complement Activation During Hemodialysis....Pages 19-26 Neutrophil Activation During Hemodialysis....Pages 27-37 Biocompatibility — A System Approach....Pages 39-52 Treatment of Uraemic Anaemia with Recombinant Human Erythropoietin....Pages 53-59 Endocrine Abnormalities in Patients with Endstage Renal Failure....Pages 61-67 Carnitine Supplementation in Uremia....Pages 69-77 Pathophysiology and Treatment of Hypertension in Dialysis Patients....Pages 79-91 Adjustment of Drug Dosage to Hemodialysis Patients....Pages 93-103 Pharmacokinetic Aspects of Drug Transport in Continuous Ambulatory Peritoneal Dialysis....Pages 105-116 Drug Therapy During Continuous Arteriovenous Hemofiltration....Pages 117-127 The Biology of the Peritoneal Membrane During Chronic Peritoneal Dialysis....Pages 129-133 Lymphatic Absorption During Peritoneal Dialysis....Pages 135-138 CAPD with Bicarbonate Solution....Pages 139-147 Glucose Polymer as an Osmotic Agent in CAPD....Pages 149-156 Effects of Long-Term Treatment with Human Recombinant Erythropoietin in Patients on CAPD....Pages 157-165 Continuous Arterio-Venous Hemofiltration: Optimization of Technical Procedures and New Directions....Pages 167-179 Is Continuous Haemofiltration Superior to Intermittent Dialysis and Haemofiltration Treatment?....Pages 181-192 Therapeutic Apheresis Update....Pages 193-201 Treatment Combining Plasmapheresis and Pulse Cyclophosphamide in Severe Systemic Lupus Erythematosus....Pages 203-213 Back Matter....Pages 215-218